Your browser doesn't support javascript.
loading
Loss of chromosome 9p21 is associated with a poor prognosis in adenosquamous carcinoma of the pancreas.
Jiang, Yina; Wu, Yinying; Zhang, Liwen; Wang, Yan; Xu, Guiping; Deng, Yuan; Han, Liang; Li, Enxiao; Ma, Qingyong; Xu, Mian; Wu, Zheng; Wang, Zheng.
Afiliação
  • Jiang Y; Department of Pathology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 70061, China.
  • Wu Y; Pancreatic disease treatment center, Xi'an Jiaotong University, Xi'an 70061, China.
  • Zhang L; Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 70061, China.
  • Wang Y; Pancreatic disease treatment center, Xi'an Jiaotong University, Xi'an 70061, China.
  • Xu G; OrigiMed Co. Ltd, Shanghai 201114, China.
  • Deng Y; OrigiMed Co. Ltd, Shanghai 201114, China.
  • Han L; Department of Radiology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 70061, China.
  • Li E; Pancreatic disease treatment center, Xi'an Jiaotong University, Xi'an 70061, China.
  • Ma Q; Department of Pathology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 70061, China.
  • Xu M; Pancreatic disease treatment center, Xi'an Jiaotong University, Xi'an 70061, China.
  • Wu Z; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 70061, China.
  • Wang Z; Pancreatic disease treatment center, Xi'an Jiaotong University, Xi'an 70061, China.
Precis Clin Med ; 6(4): pbad030, 2023 Dec.
Article em En | MEDLINE | ID: mdl-38024139
ABSTRACT
Adenosquamous carcinoma of the pancreas (ASCP) is a rare histological subtype of pancreatic cancer with a poor prognosis and a high metastasis rate. However, little is known about its genomic landscape and prognostic biomarkers. A total of 48 ASCP specimens and 98 pancreatic ductal adenocarcinoma (PDAC) tumour specimens were sequenced to explore the genomic landscape and prognostic biomarkers. The homozygous deletion of the 9p21.3 region (including CDKN2A, CDKN2B, and MTAP) (9p21 loss) occurred in both ASCP and PDAC, and a higher frequency of 9p21 loss was observed in ASCP (12.5% vs 2.0%, P = 0.022). Notably, 9p21 loss was significantly associated with poor disease-free survival (DFS) in ASCP patients (mDFS (Median DFS) = 4.17 vs 7.33 months, HR (Hazard Ratio) = 3.70, P = 0.009). The most common gene alterations in patients with ASCP were KRAS (96%), TP53 (81%), CDKN2A (42%), SMAD4 (21%), CDKN2B (13%), and FAT3 (13%). The mutation rates of ACVR2A (6.25% vs 0%), FANCA (6.25% vs 0%), RBM10 (6.25% vs 0%), and SPTA1 (8.33% vs 1.02%) were significantly higher in ASCP than in PDAC. In conclusion, we have comprehensively described the genomic landscape of the largest cohort of ASCP patients to date and highlight that 9p21 loss may be a promising prognostic biomarker for ASCP, which provides a molecular basis for prognosis prediction and new therapeutic strategies for ASCP.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Precis Clin Med Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Precis Clin Med Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China